Myriad Gene Patent Fight: Biotech And Pharma Are Ringside For Round Two

Industry wants a narrow decision as the Biotechnology Industry Organization urges the Federal Circuit to protect composition of matter claims in reconsidering the ACLU’s suit against Myriad; Lilly calls for the court to create a bright patent-eligibility line.